arrow
Back
T

Timothy A. Yap

The University of Texas MD Anderson Cancer Center

77H-index
1.4KPaper Count
2.7WCitation Count
Published Papers 222
Publication Date
Modernizing renal eligibility in oncology trials
err2026-07-28
err0
errOAAI
errHarold Nathan Tan; Sreedhar Mandayam; Prabir Roy-Chaudhury; Timothy A. Yap
errShare
errSave
Targeting genomic instability in cancer
errCell
IF42.5
err2026-04-16
err0
PREAI
errTimothy A. Yap; H. Charles Manning; Puja Sapra; Gordon B. Mills; Mark J. O’Connor
errShare
errSave
Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology
err2026-02-24
err0
errOAAI
errStephanie T. Schmidt; Mehmet A. Baysal; Siqing Fu; David S. Hong; Sarina A. Piha-Paul; Aung Naing; Jordi Rodon Ahnert; Timothy A. Yap; Ecaterina Elena Dumbrava; Jennifer Beck; Funda Meric-Bernstam; Apostolia Maria Tsimberidou
errShare
errSave
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial
err2026-01-13
err0
errOAAI
errTimothy A. Yap; Randy F. Sweis; Ulka Vaishampayan; Deepak Kilari; Justin F. Gainor; Meredith McKean; Minal Barve; Ahmad A. Tarhini; Bruno Bockorny; Guru Sonpavde; David Park; Sunil Babu; Yawen Ju; Lan Liu; Susan Henry; Giridhar S. Tirucherai; Stephen DeWall; Mohammed Qatanani; Jing L. Marantz; Lu Gan
errShare
errSave
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology
err2026-01-05
err0
PREAI
errAmber Johnson; Yifei Shen; Xiaofeng Zheng; Fei Su; Jia Zeng; Burak Uzunparmak; Eun-Kyoung Breuer; Vijaykumar Holla; Michael Kahle; Sun-Hee Kim; Thuy Vu; Kenna R. Mills Shaw; Ecaterina Ileana Dumbrava; Timothy A. Yap; Jordi Rodon; Mark Routbort; Keyur Patel; Shashikant Kulkarni; Donna Hansel; Julian Bryan; Anil Korkut; Ken Chen; Funda Meric-Bernstam
errShare
errSave
Circulating tumor DNA as a biomarker in early phase clinical trials
err2025-12-18
err0
PREAI
errHarold N. Tan; Mitchell J. Elliott; Ian M. Silverman; Lillian L. Siu; Timothy A. Yap
errShare
errSave
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen
err2025-12-03
err0
errOAAI
errNealia C. House; Maxine M. Chen; Sima Khazaei; Victoria Brown; Philip Ramsden; David H. Peng; Sydney Moore; Liang Yuan; Rentian Wu; Fangyang Wang; Linjie Luo; Ningping Feng; Christopher A. Bristow; Timothy A. Yap; Khandan Keyomarsi; Joseph R. Marszalek; Scott Ribich; Mikael L. Rinne; Lakshmi B. Muthuswamy; Kerrie L. Faia
errShare
errSave
errShare
errSave
Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations
err2025-11-11
err0
errOAAI
errS.A. Piha-Paul; C. Tseng; H.T. Tran; S. Fu; E.E. Dumbrava; T.A. Yap; A. Naing; J. Lim; M.B. Murphy; D.L. Ramirez; P.T. Soliman; A.K. Sood; F. Meric-Bernstam
errShare
errSave
Drugging the DNA damage response in the clinic: going beyond PARP
err2025-10-25
err0
PREAI
errCarlos Torrado; Alvaro Gonzalez-Ortiz; Camila B. Xavier; Harold N. Tan; Natalie Y. L. Ngoi; Timothy A. Yap
errShare
errSave
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial
err2025-10-19
err0
PREAI
errTimothy A. Yap; David J. Kwiatkowski; Ibiayi Dagogo-Jack; Michael Offin; Marjorie G. Zauderer; Robert Kratzke; Jayesh Desai; Amy Body; Michael Millward; Anthony W. Tolcher; Kanwal P. S. Raghav; Archie Thurston; Len Post; F. Andrew Dorr; Tracy T. Tang; Yufeng Li; Neelesh Sharma; Hedy L. Kindler
errShare
errSave
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib
err2025-08-21
err0
errOAAI
errJatinder Kaur Mukker; Paul Matthias Diderichsen; Farina Hellmann; Timothy A. Yap; Ruth Plummer; Anthony W. Tolcher; Johann S. de Bono; Ioannis Gounaris; Zoltan Szucs; Astrid Zimmermann; Irina Kareva; Jayaprakasam Bolleddula; Annick Seithel-Keuth; Giuseppe Locatelli; Marta Enderlin; Christine Hicking; Anup Zutshi; Wei Gao; Rainer Strotmann; Lisa Benincosa; Karthik Venkatakrishnan
errShare
errSave
Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanoma
err2025-07-07
err0
errOAAI
errNatalie Y. L. Ngoi; Ian M. Silverman; Adrienne Johnson; Chenfeng Meng; Joseph D. Schonhoft; Michal Zimmermann; Danielle Ulanet; Hyeyeon Kim; Carlos Torrado; Carolina Salguero; Christian Valladolid Brown; Jordi Rodon; Victoria Rimkunas; Maria Koehler; Timothy A. Yap
errShare
errSave
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies
err2025-06-14
err0
errOAAI
errFederica Giugliano; Carmine De Angelis; Barbara Pistilli; Giulia Viale; Giampaolo Bianchini; Mario Giuliano; Luca Malorni; Beatrice Taurelli Salimbeni; Angela Esposito; Antonio Giordano; Timothy A. Yap; Giuseppe Curigliano; Carmen Criscitiello
errShare
errSave
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study
err2025-05-17
err0
errOAAI
errYap, Timothy A.; LoRusso, Patricia; Miller, Rowan E.; Kristeleit, Rebecca; Paulovich, Amanda G.; McMorn, Stephen; O'Connor, Lenka Oplustil; Lombardi, Benedetta; Marco-Casanova, Paola; Gangl, Eric T.; Patel, Bharat; O'Connor, Mark J.; Dean, Emma; Zviezdin, Roman; Plummer, Ruth
errShare
errSave
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study (vol 40, pg 290, 2022)
err2025-02-20
err0
errOAAI
errThein, Kyaw Z.; Karp, Daniel D.; Tsimberidou, Apostolia; Gong, Jing; Sulovic, Selma; Shah, Jatin; Milton, Denai R.; Hong, David S.; Janku, Filip; Mcquinn, Lacey; Stephen, Bettzy A.; Colen, Rivka; Carter, Brett W.; Yap, Timothy A.; Piha-Paul, Sarina A.; Fu, Siqing; Meric-Bernstam, Funda; Naing, Aung
errShare
errSave
Early tolerance and late persistence as alternative drug responses in cancer
err2025-02-03
err0
errOAAI
errPunzi, Simona; Cittaro, Davide; Gatti, Guido; Crupi, Gemma; Botrugno, Oronza A.; Cartalemi, Antonino Alex; Gutfreund, Alon; Oneto, Caterina; Giansanti, Valentina; Battistini, Chiara; Santacatterina, Giovanni; Patruno, Lucrezia; Villanti, Ilaria; Palumbo, Martina; Laverty, Daniel J.; Giannese, Francesca; Graudenzi, Alex; Caravagna, Giulio; Antoniotti, Marco; Nagel, Zachary; Cavallaro, Ugo; Lanfrancone, Luisa; Yap, Timothy A.; Draetta, Giulio; Balaban, Nathalie; Tonon, Giovanni
errShare
errSave
Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations
err2025-02-01
err0
errOAAI
errPiha-Paul, S. A.; Tseng, C.; Tran, H. T.; Naing, A.; Dumbrava, E. E.; Karp, D. D.; Rodon, J.; Yap, T. A.; Raghav, K. P.; Damodaran, S.; Le, X.; Soliman, P. T.; Lim, J.; Meric-Bernstam, F.
errShare
errSave
A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers
errCANCER
IF5.1
err2025-01-23
err0
PREAI
errAhmed, Jibran; Janku, Filip; Karp, Daniel D.; Piha-Paul, Sarina A.; Tsimberidou, Apostolia M.; Yap, Timothy Anthony; Stephen, Bettzy; Yang, Yali; Gurses, Serdar; Liu, Qian; Song, Juhee; Meric-Bernstam, Funda; Naing, Aung
errShare
errSave